Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177718 · ClinicalTrials.gov registry record · Phase 4
Natalizumab and Chronic Inflammation
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT05177718 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT05177718, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
Interventions
- DRUG Natalizumab 300 MG in 15 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05177718
The ClinicalTrials.gov registry entry for NCT05177718 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natalizumab 300 MG in 15 ML Injection is the first listed.
NCT05177718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05177718 about?
NCT05177718 is a clinical study titled "Natalizumab and Chronic Inflammation". In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
What is the current status of trial NCT05177718?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2022-09-16. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT05177718?
The interventions under investigation include: Natalizumab 300 MG in 15 ML Injection (DRUG).
Who is sponsoring clinical trial NCT05177718?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.